In Frail Elderly Patients, Low-Dose Gemcitabine over 6-Hour Infusion Is Equally Effective and Less Toxic Than the Standard Gemcitabine Protocol for Advanced Pancreatic Adenocarcinoma: A Randomized Phase II Trial
- 1 Medical Oncology Department, South Egypt Cancer Institute, Assiut University, Assiut, Egypt
- 2 Clinical Oncology and Nuclear Medicine Department, Sohag University, Sohag, Egypt
- 3 Clinical Oncology and Nuclear Medicine Department, Sohag University, Sohag, Egypt
- 4 Clinical Oncology and Nuclear Medicine Department, Sohag University, Sohag, Egypt
- 5 Surgical Oncology Department, South Egypt Cancer Institute, Assiut University, Assiut, Egypt
- 6 Division of gastroenterology-Department of internal medicine, Assiut University, Assiut, Egypt
- 7 Radiation Oncology Department, South Egypt Cancer Institute, Assiut University, Assiut, Egypt
- 8 Radiation Oncology Department, South Egypt Cancer Institute, Assiut University, Assiut, Egypt
Abstract
Background: Treatment of frail elderly patients with pancreatic cancer is still a major problem due to intolerance to standard chemotherapy doses. Aim: This study aims to compare the low-dose gemcitabine over 6 hours (LD6H) to the standard gemcitabine protocol in terms of clinical benefit, survival, and safety in the frail elderly patients with advanced pancreatic adenocarcinoma. Methods: Patients enrolled in this trial were randomly assigned by in a 1:1 fashion via closed envelope method to either receive gemcitabine of 1000 mg/m 2 over 30-minute infusion on days 1, 8, and 15 of every 4-week cycle (standard protocol arm) or gemcitabine as a weekly low-dose (250 mg/m 2 ) over 6-hour infusion (LD6H arm). Results: We enrolled eighty-two eligible frail elderly patients with advanced pancreatic cancer. The patients were randomly assigned to receive either standard gemcitabine protocol (40 patients) or low-dose (250 mg/m 2 ) gemcitabine over 6-hour infusion, given weekly (42 patients). There was no significant difference between the standard group and low-dose group as regard of the overall response rate (p = 0.654), the disease control rate (DCR) (p = 0.845), the median progression-free survival (PFS) (p = 0.908) and the overall survival (OS) (p = 0.331). The low-dose regimen had a significantly lower incidence of adverse effects grades 3 or 4 when compared to the standard regimen: (p = 0.024 for fatigue, p = 0.027 for hypotension, p = 0.012 for each anemia as well as thrombocytopenia, and p = 0.006 for neutropenia). Conclusion: Low-dose gemcitabine over 6-hour infusion is equally effective and less toxic when compared to standard gemcitabine protocol in frail elderly patients with advanced pancreatic adenocarcinoma. So, we recommend the low-dose gemcitabine for frail elderly patients with advanced pancreatic cancer.
- Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R.L., Torre, L.A. and Jemal, A. (2018) Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 68, 394-424. https://doi.org/10.3322/caac.21492
- Rawla, P., Sunkara, T. and Gaduputi, V. (2019) Epidemiology of Pancreatic Cancer: Global Trends, Etiology and Risk Factors. World Journal of Oncology, 10, 10-27. https://doi.org/10.14740/wjon1166
- Burris, H.A., Moore, M.J., Andersen, J., Green, M.R., Rothenberg, M.L., Modiano, M.R., et al. (1997) Improvements in Survival and Clinical Benefit with Gemcitabine as First-Line Therapy for Patients with Advanced Pancreas Cancer: A Randomized Trial. Journal of Clinical Oncology, 15, 2403-2413. https://doi.org/10.1200/JCO.1997.15.6.2403
- Conroy, T., Desseigne, F., Ychou, M., Bouché, O., Guimbaud, R., Bécouarn, Y., et al. (2001) Groupe Tumeurs Digestives of Unicancer. PRODIGE Intergroup. FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer. The New England Journal of Medicine, 364, 1817-1825. https://doi.org/10.1056/NEJMoa1011923
- Von Hoff, D.D., Ervin, T., Arena, F.P., Chiorean, E.G., Infante, J., Moore, M., et al. (2013) Increased Survival in Pancreatic Cancer with Nab-Paclitaxel plus Gemcitabine. The New England Journal of Medicine, 369, 1691-1703. https://doi.org/10.1056/NEJMoa1304369
- Macchini, M., Chiaravalli, M., Zanon, S., Peretti, U., Mazza, E., Gianni, L., et al. (2019) Chemotherapy in Elderly Patients with Pancreatic Cancer: Efficacy, Feasibility and Future Perspectives. Cancer Treatment Reviews, 72, 1-6. https://doi.org/10.1016/j.ctrv.2018.10.013
- Rockwood, K., Song, X., MacKnight, C., Bergman, H., Hogan, D.B., McDowell, I., et al. (2005) A Global Clinical Measure of Fitness and Frailty in Elderly People. Canadian Medical Association Journal, 173, 489-495. https://doi.org/10.1503/cmaj.050051
- Turner, G. and Clegg, A. (2014) Best Practice Guidelines for the Management of Frailty: A British Geriatrics Society, Age UK and Royal College of General Practitioners Report. Age Ageing, 43, 744-747. https://doi.org/10.1093/ageing/afu138
- Raiche, M., Hebert, R. and Dubois, M.F. (2008) Prisma-7: A Case Finding Tool to Identify Older Adults with Moderate to Severe Disabilities. Archives of Gerontology and Geriatrics, 47, 9-18. https://doi.org/10.1016/j.archger.2007.06.004
- Hubbard, R.E., Peel, N.M., Samanta, M., Gray, L.C., Fries, B.E., Mitnitski, A. and Rockwood, K. (2015) Derivation of a Frailty Index from the Interrai Acute Care Instrument. BMC Geriatrics, 15, 27. https://doi.org/10.1186/s12877-015-0026-z